Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.53 |
| ▸ | RAD52 | P43351 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.49 |
| ▸ | ACP1 | P24666 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17829576 | 0.94 | RAD52 (0.55) | TLR9RAD52POLBKMT2AMEN1 | |
| SCHEMBL17829589 | 0.90 | RAD52 (0.48) | TLR9RAD52POLBKMT2AMEN1 | |
| SCHEMBL17829844 | 0.89 | RAD52 (0.48) | TLR9RAD52POLBKMT2ASMARCA2 | |
| SCHEMBL17829839 | 0.89 | RAD52 (0.50) | TLR9RAD52POLBKMT2AMEN1 | |
| SCHEMBL17829891 | 0.89 | RAD52 (0.44) | TLR9RAD52POLBKMT2AMEN1 | |
| SCHEMBL17829872 | 0.87 | RAD52 (0.52) | TLR9RAD52POLBKMT2AMEN1 | |
| SCHEMBL17829877 | 0.87 | RAD52 (0.46) | TLR9RAD52POLBKMT2ASMARCA2 | |
| SCHEMBL17829952 | 0.86 | SYK (0.49) | RAD52KMT2AACP1ALDH1A1MAPK1 | |
| SCHEMBL17829915 | 0.86 | GBA1 (0.40) | TLR9RAD52POLBKMT2AMEN1 | |
| SCHEMBL17829883 | 0.86 | ALDH1A1 (0.54) | TLR9RAD52POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | TLR9 105/4885RAD52 1940/4885POLB 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.